Evidence map›Paper›PMID 39821265›Full record

ArticleJournal of medical virology2025

USP7 Inhibitors Destabilize EBNA1 and Suppress Epstein-Barr Virus Tumorigenesis.

Christopher Chen, Kush Addepalli, Samantha S Soldan, Leonardo Josue Castro-Munoz, Sarah Preston-Alp, Rishi J Patel, Coltin J Albitz, Hsin-Yao Tang, Italo Tempera, Paul M Lieberman

Abstract read
In one paragraph

Article in Journal of medical virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Christopher ChenThe Wistar Institute, Philadelphia, Pennsylvania, USA.
Kush AddepalliUniversity of Pennsylvania, Philadelphia, Pennsylvania, USA.
Samantha S SoldanThe Wistar Institute, Philadelphia, Pennsylvania, USA.
Leonardo Josue Castro-MunozThe Wistar Institute, Philadelphia, Pennsylvania, USA.
Sarah Preston-AlpThe Wistar Institute, Philadelphia, Pennsylvania, USA.
Rishi J PatelUniversity of Pennsylvania, Philadelphia, Pennsylvania, USA.
Coltin J AlbitzThe Wistar Institute, Philadelphia, Pennsylvania, USA.
Hsin-Yao TangThe Wistar Institute, Philadelphia, Pennsylvania, USA.
Italo TemperaThe Wistar Institute, Philadelphia, Pennsylvania, USA.ORCID 0000-0001-7893-2914
Paul M LiebermanThe Wistar Institute, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-3935-9921

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Aaron Robert Goldman · 1985 to 2026
$75.9M
TRAINING PROGRAM IN BASIC CANCER RESEARCHT32CA009171 · NCI · WISTAR INSTITUTE · PI Alessandro Gardini · 1985 to 2026
$15.3M
Targeting the Epigenetic and Metabolic Control of EBV-Epithelial CancersP01CA269043 · NCI · WISTAR INSTITUTE · PI Italo Tempera · 2023 to 2026
$12.0M
Virus, Vector and Cell Culture CoreP01CA281867 · NCI · UNIVERSITY OF PENNSYLVANIA · PI ERLE S. ROBERTSON · 2023 to 2026
$9.1M
Regulation of Epstein-Barr Virus LatencyR01CA093606 · NCI · WISTAR INSTITUTE · PI LIEBERMAN, PAUL M. · 2002 to 2022
$6.7M
Epigenetic Regulation of Epstein-Barr Virus Latency ProgramsR01DE017336 · NIDCR · WISTAR INSTITUTE · PI PAUL M. LIEBERMAN · 2005 to 2026
$6.5M
Role of TERRA in Telomere Maintenance and Telomere Stress ResponseR01CA140652 · NCI · WISTAR INSTITUTE · PI LIEBERMAN, PAUL M. · 2010 to 2025
$6.0M
Drugging EBNA1 to Treat EBV-Associated Cancers - Diversity SupplementR01CA259171 · NCI · WISTAR INSTITUTE · PI MESSICK, TROY E · 2021 to 2025
$3.3M
Advancing Cancer Research through Comprehensive Proteomics and Metabolomics AnalysesR50CA221838 · NCI · WISTAR INSTITUTE · PI Hsin-Yao Tang · 2017 to 2026
$2.1M
Unique Genomic Regions of Y pestis in PathogenesisR21AI053508 · NIAID · UNIVERSITY OF CALIF-LAWRNC LVRMR NAT LAB · PI GARCIA, EMILIO · 2002 to 2003
$529k
NCI NIH HHS P01 CA269043NCI NIH HHS P01 CA281867NCI NIH HHS P30 CA010815NCI NIH HHS R01 CA093606NCI NIH HHS R01 CA140652NCI NIH HHS R01 CA259171NCI NIH HHS R50 CA221838NCI NIH HHS T32 CA009171NIAID NIH HHS R21 AI053508NIDCR NIH HHS R01 DE017336This work was supported by R01 CA259171, P01 CA269043, R01 AI53508 (PML), P30 Cancer Center Support Grant P30 CA010815 (D. Altieri), T32 CA009171 to CC. The funders provided salary support for PML, SSS, LJCM (NIH DE017336, AI53508, CA140652, CA093606, CA2059171-02S1, HYT (R50 CA221838), and CC (T32 CA009171).
6 · The paper itself

Abstract

Epstein-Barr virus (EBV) is a ubiquitous human ɣ-herpesvirus implicated in various malignancies, including Burkitt's lymphoma and gastric carcinomas. In most EBV-associated cancers, the viral genome is maintained as an extrachromosomal episome by the EBV nuclear antigen-1 (EBNA1). EBNA1 is considered to be a highly stable protein that interacts with the ubiquitin-specific protease 7 (USP7). Here, we show that pharmacological inhibitors and small interfering RNA (siRNA) targeting USP7 reduce EBNA1 protein levels in a proteosome-dependent manner. Proteomic analysis revealed that USP7 inhibitor GNE6776 altered the EBNA1 protein interactome, including disrupting USP7 association with EBNA1. GNE6776 also inhibited EBNA1 binding to EBV oriP DNA and reduced viral episome copy number. Transcriptomic studies revealed that USP7 inhibition affected chromosome segregation and mitotic cell division pathways in EBV

Indexed as

CarcinogenesisEpstein-Barr Virus InfectionsEpstein-Barr Virus Nuclear AntigensHerpesvirus 4, HumanUbiquitin-Specific Peptidase 7AnimalsHumansMiceEBV-encoded nuclear antigen 1Epstein-Barr Virus Nuclear AntigensUbiquitin-Specific Peptidase 7USP7 protein, humanEBNA1EBVgastric cancerinhibitorUSP7

Identifiers

PMID39821265
PMCPMC11740287

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.